Skip to content
Screener

Eton Pharmaceuticals, Inc. ETON Cash & Equivalents

Cash & Equivalents at other companies

HRO
HarrowHROW
$83.89M+58.4%
XER
Xeris Biopharma Holdings, Inc.XERS
$121.75M+105%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$360.25M+65.4%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$145.32M+205%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$125M-29.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$24.47M-46.6%

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K—
Free cash flow$7.3M+251%

Valuation

See full
Market cap$1.26B+209%
Enterprise value$1.28B+208%
P/S14.6×+7.5×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%—
Net margin-9.5%-2.7pp
FCF margin17.1%—

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity1×-0.2×
Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:17 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001437749-26-017064
Line itemMarch 31, 2026December 31, 2025
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$19,661$25,942
Accounts receivable, net13,40811,757
Inventories, net14,46715,419
Prepaid expenses and other current assets5,7097,463
Total current assets53,24560,581

Document

FAQ

What is Eton Pharmaceuticals, Inc.'s cash & equivalents?
Eton Pharmaceuticals, Inc. (ETON) reported cash & equivalents of $19.66M in Q1 2026.
How has Eton Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
Eton Pharmaceuticals, Inc.'s cash & equivalents increased by 12.9% year-over-year, from $17.42M to $19.66M.
What is the long-term trend for Eton Pharmaceuticals, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s cash & equivalents has grown at a 4.0% compound annual growth rate (CAGR), from $21.3M to $25.94M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Eton Pharmaceuticals, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude